Medical Tech Stock Aethlon Medical, Inc. (NASDAQ: $AEMD) on the Move – Morning High of $2.09

 

 

 

Medical Tech Stock Aethlon Medical, Inc. (NASDAQ: $AEMD) on the Move – Morning High of $2.09

 

 

 

 

(Investorideas.com Newswire) Investorideas.com, a leading investment platform for retail investors issues a trading and news alert for  Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases.

The stock is building on yesterday’s gains, currently trading at $1.96, up 0.23, gaining over 13%. Aethlon has a morning high of $2.09 as of this report.

 

Paid News Dissemination of behalf of AEMD

 

Read this news, featuring AEMD in full at https://www.investorideas.com/CO/AEMD/news/2026/03131-aethlon-aemd-stock-on-the-move.asp

 

Aethlon Medical, Inc. (Nasdaq: AEMD) announced yesterday  that it is evaluating a range of strategic opportunities and has engaged Maxim Group LLC (“Maxim”) to act as the Company’s exclusive financial advisor in connection with this process.

 

The Company engaged Maxim following preliminary inbound interest regarding potential strategic opportunities.  Maxim will assist the Company in reviewing a range of potential transactions, including partnerships, mergers, acquisitions or other opportunities involving the Company.

 

James Frakes, Chief Executive Officer and Chief Financial Officer of Aethlon stated, “The Company continues to execute its development activities, having completed the second cohort of our Australian oncology trial.   Safety data from that cohort will be submitted to the independent Data Safety Monitoring Board for review.   At the same time, we are evaluating strategic alternatives with the assistance of Maxim as part of our ongoing efforts to assess opportunities available to the Company and its shareholders.”

 

The Company has not established a definitive timeline for this evaluation and can provide no assurance that any transaction will result from this process.  The Company will pursue only those opportunities that the Board believes are appropriate for the Company and its shareholders.

 

 

About Aethlon Medical, Inc.

Aethlon Medical, Inc. (Nasdaq: AEMD) is a clinical-stage medical device company headquartered in San Diego, California. Aethlon is advancing the Hemopurifier, to address unmet needs in oncology and infectious disease, using a novel platform designed to selectively remove circulation pathogenic targets from biologic fluids.

For more information, visit www.AethlonMedical.com and follow the Company on LinkedIn.

 

Full news

https://www.investorideas.com/CO/AEMD/news/2026/03121-aethlon-aemd-maxim-strategic-opportunities.asp

 

Aethlon Medical Inc. (Nasdaq:AEMD) is a featured biotech stock on Investorideas.com

More info on AEMD at Investorideas.com Visit: https://www.investorideas.com/CO/AEMD/

Get News Alerts on Aethlon Medical

Disclaimer/Disclosure: Aethlon Medical, Inc. (AEMD) is a paid featured medical tech stock on Investor ideas More disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. More disclosure: Contact management and IR of each company directly regarding specific questions.

About Investorideas.com – Where you find the best investing ideas

Investorideas.com is the go-to platform for big investing ideas. From breaking stock news to top-rated investing podcasts, we cover it all

Get more biotech and medical tech news, articles, podcasts and stock directories

 

Follow us on X @investorideas

Follow us on Facebook https://www.facebook.com/Investorideas

Follow us on YouTube https://www.youtube.com/c/Investorideas

 

Sign up for free stock news alerts at Investorideas.com

https://www.investorideas.com/Resources/Newsletter.asp

 

 

 

 

Medical Tech Stock Aethlon Medical, Inc. (NASDAQ: $AEMD) Gains on News

 

 

Medical Tech Stock Aethlon Medical, Inc. (NASDAQ: $AEMD) Gains on News

 

 

 

 

(Investorideas.com Newswire) Investorideas.com, a leading investment platform for retail investors reports breaking Medical Tech Stock news for  Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases.

 

The stock gained today on news ,currently trading at 1.7300+0.0794 (+4.81%), with a day’s high of $1.94 on volume of over 859,000 shares as of this report.

 

Aethlon Medical, Inc. (Nasdaq: AEMD) today announced that it is evaluating a range of strategic opportunities and has engaged Maxim Group LLC (“Maxim”) to act as the Company’s exclusive financial advisor in connection with this process.

 

The Company engaged Maxim following preliminary inbound interest regarding potential strategic opportunities.  Maxim will assist the Company in reviewing a range of potential transactions, including partnerships, mergers, acquisitions or other opportunities involving the Company.

 

Paid News Dissemination of behalf of AEMD

 

Read this news, featuring AEMD in full at https://www.investorideas.com/CO/AEMD/news/2026/03122-aethlon-aemd-maxim-strategic-opportunities.asp

 

James Frakes, Chief Executive Officer and Chief Financial Officer of Aethlon stated, “The Company continues to execute its development activities, having completed the second cohort of our Australian oncology trial.   Safety data from that cohort will be submitted to the independent Data Safety Monitoring Board for review.   At the same time, we are evaluating strategic alternatives with the assistance of Maxim as part of our ongoing efforts to assess opportunities available to the Company and its shareholders.”

 

The Company has not established a definitive timeline for this evaluation and can provide no assurance that any transaction will result from this process.  The Company will pursue only those opportunities that the Board believes are appropriate for the Company and its shareholders.

 

About Maxim Group LLC

Founded in 2002, Maxim Group is a leading full-service investment bank, securities and wealth management firm headquartered in Midtown Manhattan providing a comprehensive array of financial services including investment banking, global institutional sales, equity research, fixed income and derivative sales & trading, merchant capital, private wealth management, and prime brokerage services to a diverse range of corporate clients, institutional investors and high-net-worth individuals. Maxim Group is a registered broker-dealer with the U.S. Securities and Exchange Commission and the Municipal Securities Rulemaking Board (MSRB). To learn more about Maxim Group, visit www.maximgrp.com.

 

About Aethlon Medical, Inc.

Aethlon Medical, Inc. (Nasdaq: AEMD) is a clinical-stage medical device company headquartered in San Diego, California. Aethlon is advancing the Hemopurifier, to address unmet needs in oncology and infectious disease, using a novel platform designed to selectively remove circulation pathogenic targets from biologic fluids.

For more information, visit www.AethlonMedical.com and follow the Company on LinkedIn.

 

Full news

https://www.investorideas.com/CO/AEMD/news/2026/03121-aethlon-aemd-maxim-strategic-opportunities.asp

 

Aethlon Medical Inc. (Nasdaq:AEMD) is a featured biotech stock on Investorideas.com

 

More info on AEMD at Investorideas.com Visit: https://www.investorideas.com/CO/AEMD/

 

Get News Alerts on Aethlon Medical

 

Disclaimer/Disclosure: Aethlon Medical, Inc. (AEMD) is a paid featured medical tech stock on Investor ideas More disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. More disclosure: Contact management and IR of each company directly regarding specific questions.

 

About Investorideas.com – Where you find the best investing ideas

Investorideas.com is the go-to platform for big investing ideas. From breaking stock news to top-rated investing podcasts, we cover it all

Get more biotech and medical tech news, articles, podcasts and stock directories

  

Follow us on X @investorideas

Follow us on Facebook https://www.facebook.com/Investorideas

Follow us on YouTube https://www.youtube.com/c/Investorideas

 

Sign up for free stock news alerts at Investorideas.com

https://www.investorideas.com/Resources/Newsletter.asp

 

 

 

 

Medical Tech Stock Aethlon Medical, Inc. (NASDAQ: $AEMD) Engages Maxim Group LLC to Evaluate Strategic Opportunities

 

 

 

Medical Tech Stock Aethlon Medical, Inc. (NASDAQ: $AEMD) Engages Maxim Group LLC to Evaluate Strategic Opportunities

 

 

 

 

 (Investorideas.com Newswire) Investorideas.com, a leading investment platform for retail investors reports breaking Medical Tech Stock news for  Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases.

Aethlon Medical, Inc. (Nasdaq: AEMD) today announced that it is evaluating a range of strategic opportunities and has engaged Maxim Group LLC (“Maxim”) to act as the Company’s exclusive financial advisor in connection with this process.

 

The Company engaged Maxim following preliminary inbound interest regarding potential strategic opportunities.  Maxim will assist the Company in reviewing a range of potential transactions, including partnerships, mergers, acquisitions or other opportunities involving the Company.

 

Paid News Dissemination of behalf of AEMD

Read this news, featuring AEMD in full at https://www.investorideas.com/CO/AEMD/news/2026/03121-aethlon-aemd-maxim-strategic-opportunities.asp

 

James Frakes, Chief Executive Officer and Chief Financial Officer of Aethlon stated, “The Company continues to execute its development activities, having completed the second cohort of our Australian oncology trial.   Safety data from that cohort will be submitted to the independent Data Safety Monitoring Board for review.   At the same time, we are evaluating strategic alternatives with the assistance of Maxim as part of our ongoing efforts to assess opportunities available to the Company and its shareholders.”

 

The Company has not established a definitive timeline for this evaluation and can provide no assurance that any transaction will result from this process.  The Company will pursue only those opportunities that the Board believes are appropriate for the Company and its shareholders.

 

About Maxim Group LLC

Founded in 2002, Maxim Group is a leading full-service investment bank, securities and wealth management firm headquartered in Midtown Manhattan providing a comprehensive array of financial services including investment banking, global institutional sales, equity research, fixed income and derivative sales & trading, merchant capital, private wealth management, and prime brokerage services to a diverse range of corporate clients, institutional investors and high-net-worth individuals. Maxim Group is a registered broker-dealer with the U.S. Securities and Exchange Commission and the Municipal Securities Rulemaking Board (MSRB). To learn more about Maxim Group, visit www.maximgrp.com.

 

About Aethlon Medical, Inc.

Aethlon Medical, Inc. (Nasdaq: AEMD) is a clinical-stage medical device company headquartered in San Diego, California. Aethlon is advancing the Hemopurifier, to address unmet needs in oncology and infectious disease, using a novel platform designed to selectively remove circulation pathogenic targets from biologic fluids.

For more information, visit www.AethlonMedical.com and follow the Company on LinkedIn.

 

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 that involve risks and uncertainties. Statements containing words such as "may," "believe," "anticipate," "expect," "intend," "plan," "project," "will," "projections," "estimate," "potentially" or similar expressions constitute forward-looking statements. Forward-looking statements in this release include, without limitation, statements regarding the Company’s engagement of Maxim Group LLC, the exploration or identification of potential strategic merger and acquisition alternatives, the possibility, timing or structure of any transaction, and the potential benefits of any such transaction. Such forward-looking statements are subject to significant risks and uncertainties, and actual results may differ materially from the results anticipated in the forward-looking statements. There can be no assurance that the Company’s engagement of a financial advisor will result in the identification or consummation of any transaction. The Company may determine to suspend or terminate the exploration of strategic alternatives at any time, and no timetable has been set for completion of this process. Risks and uncertainties that could cause actual results to differ materially from those expressed or implied by these forward-looking statements include, without limitation: the Company’s ability to identify suitable transaction partners; the risk that any discussions with third parties do not result in a definitive agreement; the risk that a transaction, if agreed upon, is not consummated; potential disruption to the Company’s business as a result of the announcement or pendency of a strategic review process; the diversion of management’s time and attention; the Company’s ability to maintain compliance with Nasdaq listing standards; the Company’s ability to raise additional capital; and other risks and uncertainties described under the caption “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended March 31, 2025, and in its other filings with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. Except as may be required by law, the Company does not intend, nor does it undertake any duty, to update this information to reflect future events or circumstances or disclose developments.

This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall it constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful. Any securities that may be offered in connection with a potential transaction would be offered only pursuant to an effective registration statement or in reliance upon an applicable exemption from registration requirements.

 

Company Contacts:

Jim Frakes

Chief Executive Officer and Chief Financial Officer

Aethlon Medical, Inc.

Jfrakes@aethlonmedical.com

 

Investor Contact:

Susan Noonan

S.A. Noonan Communications, LLC

susan@sanoonan.com

 

Aethlon Medical Inc. (Nasdaq:AEMD) is a featured biotech stock on Investorideas.com

More info on AEMD at Investorideas.com Visit: https://www.investorideas.com/CO/AEMD/

Get News Alerts on Aethlon Medical

 

Disclaimer/Disclosure: Athelon Medical, Inc. (AEMD) is a paid featured medical tech stock on Investor ideas More disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. More disclosure: Contact management and IR of each company directly regarding specific questions.

 

About Investorideas.com – Where you find the best investing ideas

Investorideas.com is the go-to platform for big investing ideas. From breaking stock news to top-rated investing podcasts, we cover it all

Get more biotech and medical tech news, articles, podcasts and stock directories

 

 

 

 

Follow us on X @investorideas

Follow us on Facebook https://www.facebook.com/Investorideas

Follow us on YouTube https://www.youtube.com/c/Investorideas

 

Sign up for free stock news alerts at Investorideas.com

https://www.investorideas.com/Resources/Newsletter.asp

 

 

 

 

AI Defense Tech Stock VisionWave Holdings (Nasdaq: $VWAV) @VWAVInc Gains on News of Transaction Update with SaverOne 2014 Ltd. (NASDAQ: $SVRE) @SaverOne_

AI Defense Tech Stock VisionWave Holdings (Nasdaq: $VWAV) @VWAVInc Gains on News of  Transaction Update with SaverOne 2014 Ltd. (NASDAQ: $SVRE) @SaverOne_

 

 

Investorideas.com, a  top 100 rated investment site for retail Investors following AI and defense stocks, reports on breaking news for VisionWave Holdings, Inc (Nasdaq: VWAV), focused on advanced sensing, autonomy, and AI-driven systems for defense and security applications.

 

The stock is trading up on news, currently at $7.32, up $0.19 on volume of over 157,000 shares.

 

VisionWave Holdings, Inc (Nasdaq: VWAV) announced the completion of Phase One of its previously announced strategic transaction with SaverOne 2014 Ltd. (NASDAQ: SVRE). The Phase One closing occurred on March 5, 2026, establishing VisionWave’s initial ownership position of approximately 19.99% in SaverOne pursuant to the companies’ definitive agreement announced January 26, 2026. The agreement provides a framework for potential additional phases that may increase VisionWave’s ownership in SaverOne to approximately 51%, subject to the achievement of technology integration and commercialization milestones.

 

The Phase One closing activates the RF sensing layer of VisionWave’s developing multi-domain sensing architecture, which integrates advanced sensing technologies, artificial intelligence infrastructure, computational acceleration and autonomous systems.

 

Paid News Dissemination on behalf of VWAV

 

Read this news, featuring VWAV in full at https://www.investorideas.com/CO/VWAV/news/2026/03112-visionwave-vwav-rf-sensing-saverone-phase-one.asp

 

Key Highlights

• Phase One closing completed March 5, 2026

• VisionWave acquired 19.99% ownership in SaverOne

• Transaction governed by January 26, 2026 definitive agreement

• Framework provides path toward potential 51% ownership

• Integration supports VisionWave’s AI-driven autonomous defense platform

 

Technology Demonstrations

SaverOne’s RF sensing technology has been demonstrated in real-world environments illustrating the ability to detect wireless signal activity and identify pedestrian presence in conditions including limited visibility and non-line-of-sight scenarios.

 

Video demonstrations of the technology can be viewed here:

RF Detection Demonstration

https://www.youtube.com/watch?v=60bMQYA9hkQ

 

Technology Overview

https://www.youtube.com/watch?v=N4tmkFhxGU0

 

Detection Demonstration

https://www.youtube.com/watch?v=haiv5zlXeeY

 

These demonstrations illustrate how RF sensing technologies may complement conventional optical sensing systems by providing detection capabilities based on wireless signal analysis.

 

Activating the RF Sensing Layer of VisionWave’s Platform

Completion of Phase One represents an expansion of VisionWave’s sensing architecture and marks the activation of the RF sensing layer within the Company’s multi-domain sensing platform.

 

VisionWave’s architecture integrates multiple sensing modalities including:

• RF detection technologies

• autonomous aerial and ground systems

• artificial intelligence processing infrastructure

• high-performance computational acceleration

The platform is designed to support advanced situational awareness capabilities across complex operational environments.

 

RF Sensing and the Electromagnetic Environment

Modern security and defense environments increasingly involve complex electromagnetic signal activity generated by wireless devices, drones, sensors and communication systems. RF-based sensing technologies analyze these signal environments and identify electronic emissions that may indicate the presence of devices, vehicles or aerial platforms. VisionWave intends to evaluate how RF detection capabilities may complement its broader sensing initiatives including counter-drone detection technologies and autonomous systems platforms.

 

Growing Demand for Advanced Sensing Platforms

Governments and infrastructure operators worldwide are increasing investment in advanced sensing and situational awareness technologies designed to detect emerging threats and support autonomous systems. Platforms integrating multiple sensing modalities—including RF detection, autonomous system sensors and AI-driven analytics—are becoming an important component of next-generation defense and security architectures.

 

Full news

https://www.investorideas.com/CO/VWAV/news/2026/03111-visionwave-vwav-rf-sensing-saverone-phase-one.asp

 

 

VisionWave Holdings is a Featured Defense stock on Investorideas.com

https://www.investorideas.com/CO/VWAV/

 

Research more defense stocks at Investorideas stock directory: https://www.investorideas.com/Companies/HomelandDefense/stock_list.asp

 

Disclaimer/Disclosure: VisionWave Holdings, Inc. is a paid for featured defense company on Investorideas.com. Investorideas is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. Contact management and IR of each company directly regarding specific questions.
More disclaimer info:  Learn more about publishing your news release and our other news services on the Investorideas.com newswire. Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy,

 

About Investorideas.com - Where you find the best investing ideas

Investorideas.com is the go-to platform for big investing ideas. From breaking stock news to top-rated investing podcasts, we cover it all.

 

Advertising agencies -Learn more about digital advertising and guest posts at Investorideas

https://www.investorideas.com/Advertise/

 

Follow & Contact

Follow us on X: @investorideas

Follow us on Facebook https://www.facebook.com/Investorideas

Follow us on YouTube @Investorideas